BioCryst Pharmaceuticals BCRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$457.98M-274% | $263.86M+3,106% | -$8.78M+75.4% | -$35.71M+33.2% | -$53.47M+39.8% | ||
| $1.52M+9.4% | $1.39M+6.5% | $1.3M+1.9% | $1.28M+0.7% | $1.27M+2.0% | ||
| $79.73M-6.3% | $85.07M+3.0% | $82.61M+1.7% | $81.26M+11.1% | $73.13M+11.8% | ||
| $313.1M-9.9% | $347.37M+592% | $50.2M— | —— | —— | ||
| $2.73M+10.5% | $2.47M+5.4% | $2.34M+122% | $1.06M+2.3% | $1.03M-8.2% | ||
| —— | —— | —— | —— | —— | ||
| -$309.44M-2,160% | -$13.69M-116% | $87.59M+6.2% | $82.51M+54.6% | $53.38M-3.0% | ||
| —— | —— | —— | —— | —— | ||
| $62.09M+118% | -$349.93M-157% | -$135.99M— | —— | —— | ||
| $66.5M+544% | -$14.99M— | —— | —— | —— | ||
| $310.37M-10.0% | $344.9M+621% | $47.86M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioCryst Pharmaceuticals generate?
- BioCryst Pharmaceuticals (BCRX) generated $313.1M in operating cash flow over the trailing twelve months.
- What is BioCryst Pharmaceuticals's free cash flow?
- After $2.7M of capital expenditures, BioCryst Pharmaceuticals's free cash flow was $310.4M over the trailing twelve months, up 448.8% year over year.
- Where does BioCryst Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
